Categories: world

Louisiana continues with “Netflix” subscription model to buy hepatitis C drugs

January 11, 2019 Health 0 Views A Fter months of consideration, Louisiana officials continue with plans for a so-called Netflix payment model to get hepatitis C treatments at an affordable price. Specifically, the state seeks drug manufacturers who would be willing to deliver treatments unlike subscription-based payments. Essentially, the state would agree to pay a fixed amount of money over five years for unlimited access to medication for anyone enrolled in the state Medicaid program or imprisoned in a state prison. Unlock this article by subscribing to the STAT Plus and enjoy your first 30 days for free! GETTING STARTED What is it? STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team of decades of industry experience. What is included? Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis and first look at pioneering laboratories and early research Only network events and panel discussions across the country ] Monthly subscribers-only live chats with our reporters and experts in the field Discounted tickets for industry events and access to early bird for industry reports Ed Silverman Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Source link

A Fter months of consideration, Louisiana officials continue with plans for a so-called Netflix payment model to get hepatitis C treatments at an affordable price.

Specifically, the state seeks drug manufacturers who would be willing to deliver treatments unlike subscription-based payments. Essentially, the state would agree to pay a fixed amount of money over five years for unlimited access to medication for anyone enrolled in the state Medicaid program or imprisoned in a state prison.

Unlock this article by subscribing to the STAT Plus and enjoy your first 30 days for free!

GETTING STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team of decades of industry experience.

What is included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis and first look at pioneering laboratories and early research
  • Only network events and panel discussions across the country
  • ] Monthly subscribers-only live chats with our reporters and experts in the field
  • Discounted tickets for industry events and access to early bird for industry reports


Source link

Share
Published by
Faela